ADC Therapeutics SA held its annual general meeting of shareholders on June 3, 2025. Shareholders approved the management report, annual financial statements, and consolidated financial statements for the year ended December 31, 2024. The members of the board of directors and the executive committee were discharged from liability for the year ended December 31, 2024. The net loss for the year ended December 31, 2024, will be carried forward. Several directors were elected or reelected, including Ron Squarer, Robert Azelby, Jean-Pierre Bizzari, Peter Hug, Ameet Mallik, Viviane Monges, Tyrell Rivers, Victor Sandor, and Timothy Coughlin.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。